Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X:
“Adjuvant GemCis (gemcitabine and cisplatin) vs CRT (chemoradiotherapy) with capecitabine in gallbladder cancer GECCOR-GB study in JAMA Oncology.
Phase II
Resected stage II/III
- R0 or R1 1-year DFS: %88.9 vs 77.8%
- 2-year DFS: 74.8% vs 74.8%
- Completion of planned trratment: 82% vs 62%
- Both met primary endpoint of 1-y DFS 77%“
Proceed to the study.
Source: Erman Akkus/X